We are live on ! Find out more
O

OrbiMed Portfolio holdings

AUM $5.4B
1-Year Est. Return 163.13%
This Fund
S&P 500
This Quarter Est. Return
+15.59%
1 Year Est. Return
+163.13%
3 Year Est. Return
+393.16%
5 Year Est. Return
+486.34%
10 Year Est. Return
+3,312.73%
AUM
$5.5B
AUM Growth
+$439M
Cap. Flow
-$3.35M
Cap. Flow %
-0.06%
Top 10 Hldgs %
41.65%
Holding
136
New
22
Increased
21
Reduced
31
Closed
18

Top Buys

Rank Stock Value
1
MBX
MBX Biosciences
MBX
+$87.2M
2
CRBP icon
Corbus Pharmaceuticals
CRBP
+$46.7M
3
SRPT icon
Sarepta Therapeutics
SRPT
+$42.6M
4
AMGN icon
Amgen
AMGN
+$38.4M
5
UNH icon
UnitedHealth
UNH
+$37.9M

Top Sells

Rank Stock Value
1
JANX icon
Janux Therapeutics
JANX
+$74.9M
2
THC icon
Tenet Healthcare
THC
+$59.2M
3
VRNA
Verona Pharma
VRNA
+$41.4M
4
GERN icon
Geron
GERN
+$40.6M
5
PCVX icon
Vaxcyte
PCVX
+$36.9M

Sector Composition

Rank Sector Weight
1 Healthcare 98.88%
2 Miscellaneous 1.12%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
RPTX
76
DELISTED
Repare Therapeutics
RPTX
$11.4M 0.21%
3,322,488
– –
ABCL icon
77
AbCellera Biologics
ABCL
$3.73B
$10.9M 0.2%
4,180,768
– –
PMVP icon
78
PMV Pharmaceuticals
PMVP
$75.4M
$9.65M 0.18%
6,475,291
– –
AVTX icon
79
Avalo Therapeutics
AVTX
$836M
$9.19M 0.17%
+967,000
New +$9.97M
VSTM icon
80
Verastem
VSTM
$674M
$8.56M 0.16%
2,862,448
+1,333,333
+87% +$3.62M
LYEL icon
81
Lyell Immunopharma
LYEL
$266M
$8.4M 0.15%
304,300
-15,955
-5% -$469K
OSCR icon
82
Oscar Health
OSCR
$10.1B
$7.46M 0.14%
+351,618
New +$6.33M
EVH icon
83
CALL
Evolent Health
EVH
$445M
$7.31M 0.13%
+258,400
New +$6.66M
BCAX
84
Bicara Therapeutics
BCAX
$1.49B
$6.93M 0.13%
+271,910
New +$6.93M
PASG icon
85
Passage Bio
PASG
$15.5M
$6.88M 0.12%
491,144
-15,085
-3% -$240K
PEPG icon
86
PepGen
PEPG
$198M
$6.82M 0.12%
+797,358
New +$9.43M
NKTX icon
87
Nkarta
NKTX
$206M
$6.69M 0.12%
1,480,600
+680,600
+85% +$3.87M
MRNA icon
88
CALL
Moderna
MRNA
$57.6B
$6.68M 0.12%
+100,000
New +$9.18M
SRPT icon
89
CALL
Sarepta Therapeutics
SRPT
$2.19B
$6.24M 0.11%
50,000
– –
IMA
90
ImageneBio Inc
IMA
$57M
$6.12M 0.11%
294,947
– –
FOLD
91
DELISTED
Amicus Therapeutics
FOLD
$6.09M 0.11%
570,300
– –
SRRK icon
92
Scholar Rock
SRRK
$5.71B
$5.95M 0.11%
742,300
-332,082
-31% -$2.92M
FATE icon
93
Fate Therapeutics
FATE
$277M
$5.88M 0.11%
1,680,580
+325,228
+24% +$1.27M
NSPR icon
94
InspireMD
NSPR
$36.1M
$5.72M 0.1%
2,133,405
– –
LBPH
95
DELISTED
Longboard Pharmaceuticals, Inc. Common Stock
LBPH
$5.67M 0.1%
+170,000
New +$5.85M
TELA icon
96
TELA Bio
TELA
$48M
$5.47M 0.1%
2,161,185
-296,357
-12% -$1.05M
SOLV icon
97
CALL
Solventum
SOLV
$15.5B
$4.83M 0.09%
69,300
-130,700
-65% -$7.86M
XFOR icon
98
X4 Pharmaceuticals
XFOR
$357M
$4.77M 0.09%
237,784
– –
RNAM
99
CALL
DELISTED
Avidity Biosciences
RNAM
$4.59M 0.08%
+100,000
New +$4.34M
KRYS icon
100
Krystal Biotech
KRYS
$9.91B
$4.28M 0.08%
23,500
-6,466
-22% -$1.25M
2 3
4
5 6

Similar funds

MYIA
Mount Yale Investment Advisors Denver, Colorado $5.4B AUM 28.46% 1-Year Est. Return
SCM
Shelton Capital Management Denver, Colorado $5.39B AUM 56.42% 1-Year Est. Return
BJL
Brighton Jones LLC Seattle, Washington $5.38B AUM 27.31% 1-Year Est. Return
BG
Baupost Group Boston, Massachusetts $5.42B AUM 22.93% 1-Year Est. Return
SNT
SIG North Trading Bala Cynwyd, Pennsylvania $5.42B AUM 31.03% 1-Year Est. Return
NL
NEPC LLC Boston, Massachusetts $5.36B AUM 7.83% 1-Year Est. Return
RC
Resolution Capital Sydney, NSW, Australia $5.44B AUM 27.71% 1-Year Est. Return
AC
AlphaCore Capital La Jolla, California $5.44B AUM 26.35% 1-Year Est. Return

OrbiMed's Q3 2024 Portfolio in Review

As of Q3 2024, OrbiMed held 136 positions worth $5.5B, up 8.7% from $5.06B the previous quarter. Its ten largest holdings account for 42% of the portfolio.

OrbiMed's Q3 2024 filing shows 22 new, 21 increased, 31 reduced and 18 closed positions. Its largest new stake was MBX Biosciences: 3,812,215 shares worth $99M. The largest sale was Janux Therapeutics, an estimated $74.9M.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, up from 99% a quarter earlier, followed by Miscellaneous.

  • OrbiMed's largest Q3 2024 buy was MBX Biosciences: 3,812,215 shares worth $99M.
  • OrbiMed added most to Sarepta Therapeutics in Q3 2024, an estimated $42.6M increase.
  • OrbiMed's biggest Q3 2024 reduction was Janux Therapeutics, cutting an estimated $74.9M.
  • OrbiMed fully exited Verona Pharma in Q3 2024, selling an estimated $41.4M.
  • OrbiMed's ten largest holdings make up 42% of its $5.5B portfolio in Q3 2024.
  • OrbiMed opened 22 new positions and closed 18 in Q3 2024.
  • OrbiMed's portfolio value rose 8.7% quarter-over-quarter to $5.5B.

Based on OrbiMed's 13F filing for Q3 2024, filed 14 Nov 2024.